[Efficacy of herpetic vaccine, larifan, myelopid and their combinations during herpesvirus infection in irradiated animals].
Killed vaccine against herpes simplex virus (HSV) 1 and 2, interferon inducer larifane, immunostimulant myelopide, and their combinations were sufficiently effective in immunocompromized mice inoculated intraperitoneally with HSV-1 and HSV-2 three days after a single radiation exposure. Combinations of the vaccine with myelopide or larifane had a higher protective effect than that of each of these agents alone. All of these drugs and their combinations more rapidly reduced the concentrations of the virus antigen in the organs of exposed and infected animals, although did not completely eliminate the virus, improved the cell-mediated and humoral immunity, thus improving their survival and prolonging the life span; moreover, they alleviated some immunosuppressive effects of ionizing radiation.
Alimbarova
L M
LM
Barinskiĭ
I F
IF
D028341:Activins; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D002522:Chlorocebus aethiops; D003131:Combined Modality Therapy; D006561:Herpes Simplex / Q000150:complications / Q000276:immunology / Q000628:therapy*; D007369:Interferon Inducers / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D009500:Neutralization Tests; D009842:Oligopeptides; D009930:Organic Chemicals; D010455:Peptides / Q000627:therapeutic use*; D011833:Radiation Injuries, Experimental / Q000150:complications* / Q000276:immunology; D014709:Vero Cells; D014765:Viral Vaccines / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D007369:Interferon Inducers; D009842:Oligopeptides; D009930:Organic Chemicals; D010455:Peptides; D014765:Viral Vaccines; C044147:activin B; D028341:Activins; C066530:larifan; C048617:myelopeptides